Compliance Rate
Compliance Rate
100.0%
Compliant submissions
1
Incompliant submissions
0
Total trials
1
My Organizations' Clinical Trials
Showing 375 of 833 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/31/12
End: 08/31/16
Due: 08/31/17
Phase: N/A
Priority: Normal
Start: 01/20/12
End: 02/28/13
Due: 02/28/14
Phase: N/A
Priority: Normal
Start: 07/31/10
End: 02/29/20
Due: 02/28/21
Phase: N/A
Priority: Normal
Start: 12/31/21
End: 09/30/22
Due: 09/30/23
Phase: N/A
Priority: Normal
Start: 07/15/20
End: 07/15/20
Due: 07/15/21
Phase: N/A
Priority: Normal
Start: 01/31/12
End: 11/30/15
Due: 11/30/16
Phase: N/A
Priority: Normal
Start: 10/31/07
End: 09/17/20
Due: 09/17/21
Phase: N/A
Priority: Normal
Start: 05/01/15
End: 11/01/17
Due: 11/01/18
Phase: N/A
Priority: Normal
Start: 05/01/09
End: 04/30/12
Due: 04/30/13
Phase: N/A
Priority: Normal
Start: 06/30/05
End: 06/30/15
Due: 06/30/16
Phase: N/A
Priority: Normal
Start: 05/31/14
End: 01/18/18
Due: 01/18/19
Phase: N/A
Priority: Normal
Start: 03/31/10
End: 01/13/14
Due: 01/13/15
Phase: N/A
Priority: Normal
Start: 07/31/12
End: 07/31/19
Due: 07/31/20
Phase: N/A
Priority: Normal
Start: 08/14/18
End: 03/23/20
Due: 03/23/21
Phase: N/A
Priority: Normal
Start: 08/15/24
End: 01/31/31
Due: 01/31/32
Phase: N/A
Priority: Normal
Start: 06/05/23
End: 02/22/24
Due: 02/22/25
Phase: N/A
Priority: Normal
Start: 02/29/16
End: 01/31/17
Due: 01/31/18
Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
Phase: N/A
Priority: Normal
Start: 10/25/13
End: 01/19/15
Due: 01/19/16
Phase: N/A
Priority: Normal
Start: 01/31/03
End: 06/30/08
Due: 06/30/09
Phase: N/A
Priority: Normal
Start: 04/29/21
End: 07/03/23
Due: 07/03/24
Phase: N/A
Priority: Normal
Start: 10/31/04
End: 07/31/07
Due: 07/31/08
Phase: N/A
Priority: Normal
Start: 09/30/05
End: 08/31/15
Due: 08/31/16
Phase: N/A
Priority: Normal
Start: 12/03/13
End: 04/23/15
Due: 04/23/16
Phase: N/A
Priority: Normal
Start: 05/17/23
End: 07/11/24
Due: 07/11/25
Phase: N/A
Priority: Normal
Start: 07/01/25
End: 07/01/28
Due: 07/01/29